RU2018124640A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018124640A3 RU2018124640A3 RU2018124640A RU2018124640A RU2018124640A3 RU 2018124640 A3 RU2018124640 A3 RU 2018124640A3 RU 2018124640 A RU2018124640 A RU 2018124640A RU 2018124640 A RU2018124640 A RU 2018124640A RU 2018124640 A3 RU2018124640 A3 RU 2018124640A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160023551 | 2016-02-26 | ||
KR10-2016-0023551 | 2016-02-26 | ||
PCT/KR2017/002096 WO2017146538A1 (ko) | 2016-02-26 | 2017-02-24 | 조절 t 세포 매개성 질환의 예방 또는 치료용 약학적 조성물 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018124640A3 true RU2018124640A3 (ru) | 2020-01-09 |
RU2018124640A RU2018124640A (ru) | 2020-01-09 |
RU2727900C2 RU2727900C2 (ru) | 2020-07-24 |
Family
ID=59685776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018124640A RU2727900C2 (ru) | 2016-02-26 | 2017-02-24 | Фармацевтическая композиция для предотвращения или лечения заболеваний, опосредованных регуляторными т-клетками |
Country Status (9)
Country | Link |
---|---|
US (1) | US11096967B2 (ru) |
EP (1) | EP3388514B1 (ru) |
JP (1) | JP6580791B2 (ru) |
KR (1) | KR102025417B1 (ru) |
CN (1) | CN108699524B (ru) |
AU (1) | AU2017224499B2 (ru) |
RU (1) | RU2727900C2 (ru) |
SG (2) | SG11201805468RA (ru) |
WO (1) | WO2017146538A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11058729B2 (en) * | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
CN111454888A (zh) * | 2019-01-18 | 2020-07-28 | 天津市第一中心医院 | 一种干细胞处理方法及使用该方法得到的细胞和应用 |
KR102268242B1 (ko) * | 2020-01-06 | 2021-06-23 | 에스씨엠생명과학 주식회사 | 줄기세포의 기능강화용 조성물 |
CN111481573A (zh) * | 2020-03-26 | 2020-08-04 | 卡替(上海)生物技术股份有限公司 | 牙髓间充质干细胞在制备克罗恩病治疗药物中的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2290052T3 (es) * | 1999-09-21 | 2008-02-16 | Genetics Institute, Llc | Moleculas gl50 y usos para las mismas. |
JP2008501638A (ja) * | 2004-04-23 | 2008-01-24 | ドイツ連邦共和国 | ICOS陽性細胞のinvivo枯渇によるT細胞介在病態の治療方法 |
WO2006003999A1 (ja) * | 2004-07-05 | 2006-01-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント |
CN101426533A (zh) * | 2005-12-08 | 2009-05-06 | 路易斯维尔大学研究基金会有限公司 | 免疫刺激组合物和方法 |
EP3109317A1 (en) * | 2007-10-17 | 2016-12-28 | TXCell | Tr1 cells, mesenchymal stem cells and uses thereof |
RU2540018C2 (ru) * | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
CN102740887B (zh) * | 2009-09-30 | 2015-04-15 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
EP2531216B1 (en) * | 2010-02-04 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
JP5900865B2 (ja) | 2012-04-26 | 2016-04-06 | 国立大学法人京都大学 | T細胞の分化誘導方法、t細胞の製造方法、t細胞、医薬組成物、及び、スクリーニング方法 |
ES2434853B1 (es) * | 2012-06-12 | 2014-09-30 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
WO2015088414A1 (en) * | 2013-12-13 | 2015-06-18 | Isletone Ab | Immunomodulatory compositions |
ES2717308T3 (es) * | 2014-12-06 | 2019-06-20 | Gemoab Monoclonals Gmbh | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos |
-
2017
- 2017-02-24 WO PCT/KR2017/002096 patent/WO2017146538A1/ko active Application Filing
- 2017-02-24 EP EP17756875.5A patent/EP3388514B1/en active Active
- 2017-02-24 KR KR1020170024766A patent/KR102025417B1/ko active IP Right Grant
- 2017-02-24 SG SG11201805468RA patent/SG11201805468RA/en unknown
- 2017-02-24 AU AU2017224499A patent/AU2017224499B2/en active Active
- 2017-02-24 CN CN201780009667.XA patent/CN108699524B/zh active Active
- 2017-02-24 RU RU2018124640A patent/RU2727900C2/ru active
- 2017-02-24 JP JP2018535058A patent/JP6580791B2/ja active Active
- 2017-02-24 US US16/069,486 patent/US11096967B2/en active Active
- 2017-02-24 SG SG10201912046VA patent/SG10201912046VA/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN108699524B (zh) | 2019-12-10 |
CN108699524A (zh) | 2018-10-23 |
EP3388514A1 (en) | 2018-10-17 |
JP6580791B2 (ja) | 2019-09-25 |
RU2727900C2 (ru) | 2020-07-24 |
US20190022144A1 (en) | 2019-01-24 |
SG10201912046VA (en) | 2020-02-27 |
SG11201805468RA (en) | 2018-07-30 |
WO2017146538A1 (ko) | 2017-08-31 |
KR20170101147A (ko) | 2017-09-05 |
RU2018124640A (ru) | 2020-01-09 |
AU2017224499B2 (en) | 2020-10-08 |
KR102025417B1 (ko) | 2019-09-25 |
EP3388514A4 (en) | 2018-10-24 |
JP2019501183A (ja) | 2019-01-17 |
EP3388514B1 (en) | 2023-10-25 |
AU2017224499A1 (en) | 2018-07-26 |
US11096967B2 (en) | 2021-08-24 |